Q1 2023 13F Holders as of 3/31/2023
-
Type / Class
-
Equity / Common Stock, par value $0.001
-
Shares outstanding
-
67.8M
-
Number of holders
-
156
-
Total 13F shares, excl. options
-
49.5M
-
Shares change
-
+860K
-
Total reported value, excl. options
-
$1.78B
-
Value change
-
+$25M
-
Put/Call ratio
-
0.49
-
Number of buys
-
71
-
Number of sells
-
-76
-
Price
-
$35.98
Significant Holders of Celldex Therapeutics, Inc. - Common Stock, par value $0.001 (CLDX) as of Q1 2023
197 filings reported holding CLDX - Celldex Therapeutics, Inc. - Common Stock, par value $0.001 as of Q1 2023.
Celldex Therapeutics, Inc. - Common Stock, par value $0.001 (CLDX) has 156 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 49.5M shares
of 67.8M outstanding shares and own 73% of the company stock.
Largest 10 shareholders include FMR LLC (7.08M shares), WELLINGTON MANAGEMENT GROUP LLP (4.18M shares), BlackRock Inc. (3.25M shares), RTW INVESTMENTS, LP (3.08M shares), VANGUARD GROUP INC (2.55M shares), STATE STREET CORP (2.3M shares), Polar Capital Holdings Plc (2.27M shares), Redmile Group, LLC (1.88M shares), Bellevue Group AG (1.8M shares), and RA CAPITAL MANAGEMENT, L.P. (1.73M shares).
This table shows the top 156 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.